Adults 18 to 50, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Changes in Body WeightPrimary· Baseline, 12 weeks
Body weight will be measured via clinic scale.
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-5.1
± 3.2
Time Restricted Feeding (TRF)
-6.2
± 4.1
Changes in Fat MassSecondary· Baseline, 12 weeks
Body composition will be assessed with dual-energy x-ray absorptiometry (DXA).
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-2.1
± 2.6
Time Restricted Feeding (TRF)
-2.8
± 1.8
Changes in Objectively Measured Energy Intake (Camera)Secondary· Baseline, 12 weeks
All energy intake events will be recorded using the camera function on a cell phone application
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-612.2
± 476
Time Restricted Feeding (TRF)
-647.3
± 773
Changes in Physical ActivitySecondary· Baseline, 12 weeks
Step count will be measured with activity monitors.
Group
Value
95% CI
Reduced Calorie Diet (RCD)
576
± 3172
Time Restricted Feeding (TRF)
596
± 2731
Changes in Sedentary BehaviorSecondary· Baseline, 12 weeks
Sitting time will be measured with activity monitors.
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-19.8
± 88
Time Restricted Feeding (TRF)
-0.77
± 82
6 Month Post-Intervention Follow-Up Body WeightSecondary· 24 weeks after completion of the 12-week intervention (i.e. at week 36)
Body weight will be measured via clinic scale at 6 months post-intervention
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-4.3
± 5.3
Time Restricted Feeding (TRF)
-4.9
± 5.3
6 Month Post-Intervention Follow-Up Fat MassSecondary· 24 weeks after completion of the 12-week intervention (i.e. at week 36)
Body composition will be assessed with dual-energy x-ray absorptiometry (DXA).
Group
Value
95% CI
Reduced Calorie Diet (RCD)
-2.6
± 4.4
Time Restricted Feeding (TRF)
-3.5
± 4
Sponsor's own description
The circadian timing of Energy Intake (EI) has emerged as a key factor in the regulation of body weight. Studies have suggested that eating later in the evening or at night when the circadian system is promoting sleep adversely influences weight loss. In contrast, restricting EI to a short window during waking hours and extending the length of the overnight fast (i.e., time restricted feeding, TRF) may be a practical and useful weight loss strategy. The overall objective of this proposal is to provide a foundation to inform the design of a future large-scale trial to evaluate the efficacy of TRF in generating weight loss. The investigators aims are to: 1) Assess processes critical for the success of a large-scale trial comparing the efficacy of a reduced calorie diet with time restricted feeding (RCD+TRF) versus standard RCD on weight loss; 2) Develop methodology to assess compliance to the RCD+TRF versus standard RCD program and collect preliminary data on whether the programs have differential effects on free-living behaviors (EI, appetite, physical activity, and sedentary behavior); and 3) Measure metabolic responses to RCD+TRF versus standard RCD to determine candidate mechanisms related to weight loss at 12wks and weight maintenance at 6mo post-intervention. The investigators primary hypothesis is that weight loss will be greater in the TRF group compared to the RCD group.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03802253 — Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial)
· NA
· active not recruiting
Other recruiting trials for Obesity
Currently open trials in the same condition.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
· not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
· Phase 3
· not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
· NA
· not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
· EARLY_PHASE1
· not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes
· Phase 2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 25 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03571048.